Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Ended early

CL-ImmunoDimmer Investigating Caspase 4 and Toll-like Receptor 4 Modulation by Endogenous Cardiolipin in Health and Barth Syndrome

Coordinator
The Chancellor Masters and Scholars of the University of Cambridge, United Kingdom
Runs
22 September 2025 to 21 September 2027
Status
Ended early
EU funding
€276k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101211643

What the project is doing

In the project's own words, from its summary on CORDIS.

Barth Syndrome (BTHS) is a disease characterised by reduced production of unsaturated mitochondrial cardiolipin (CL) and increased production of abnormal CL with saturated chains. Chronic inflammation and increased vulnerability to infection are major contributors to mortality in BTHS patients. The connection between these immune dysfunctions and CL modifications is not understood. My research has shown that unsaturated CL inhibits caspase 4 (CASP4) and Toll-like Receptor 4 (TLR4).

Moderate CASP4 and TLR4 activation by bacterial triggers is essential for antibacterial defence, while uncontrolled activation results in infection lethality and inflammatory disease. My preliminary data show that abnormal CL similar to the one found in BTHS patients does not inhibit CASP4, and saturated CL activates TLR4. These findings suggest that in health, unsaturated CL acts as a dimmer to fine-tune immune reactions, while in BTHS, this dimmer is compromised, resulting in immune dysfunction.

To investigate this hypothesis, this proposal ideally combines my expertise in cardiolipin and mitochondria research with the host’s expertise in gene editing and live microscopy. Using well-established methodologies, we will deplete CL from monocytes and macrophages and study how this affects CASP4 and TLR4 activation. Moreover, I will characterise BTHS immune response through the analysis of inflammatory markers in patients’ plasma, and patients’ neutrophils, monocytes and macrophages CASP4 and TLR4 response.

This will provide a deeper mechanistic understanding of inflammatory processes in both health and disease, potentially identifying CL, CASP4, and TLR4 as new targets for treating BTHS. While I will enhance the team’s multidisciplinary character and provide collaboration opportunities, I will be trained in cutting-edge techniques and get leadership and network opportunities crucial for my long-term goal of scientific independence.

Topics

Who is involved

OrganisationCityCountryRole
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI